PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Similar documents
The general concept of pharmacokinetics

PHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Quantitative Pooling of Michaelis-Menten Equations in Models with Parallel Metabolite Formation Paths

Multicompartment Pharmacokinetic Models. Objectives. Multicompartment Models. 26 July Chapter 30 1

CHAPTER 1 Role of Bioanalytical Methods in Drug Discovery and Development

Nonlinear pharmacokinetics

HANDBOOK OF DRUG ANALYSIS

Using ODEs to Model Drug Concentrations within the Field of Pharmacokinetics

MIDW 125 Math Review and Equation Sheet

ADME studies with radiolabeled compounds. Biomedical Applications of Radioisotopes and Pharmacokinetics Unit

PHARMACOKINETIC DERIVATION OF RATES AND ORDERS OF REACTIONS IN MULTI- COMPARTMENT MODEL USING MATLAB

Quantitative analysis of small molecules in biological samples. Jeevan Prasain, Ph.D. Department of Pharmacology & Toxicology, UAB.

Reaction Rate (Kinetics) Reaction Rate

Validation of the GastroPlus TM Software Tool and Applications

PHYSIO-CHEMICAL PROPERTIES OF THE DRUG. It is the interaction of the drug with its environment

FORMIC ACID in URINE by GC/MS-headspace - Code GC74010

Buffer Titrations Lab

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Phenobarbital analysis in biological matrix (blood) by high performance liquid chromatography (HPLC)

Open PHACTS Explorer: Compound by Name

FRAUNHOFER IME SCREENINGPORT

Acid-Base Properties

- A7/13 - PART 2. Matrix Analyte(s) Method LOQ Reference. HPLC with fluorescence detection after acid hydrolysis

Chemical Analysis Problem

1 Introduction 1 STA. High performance liquid chromatography (HPLC) Basic and acidic extract (plasma) Automated screening system, Bio-Rad (urine)

Chromatographic Methods of Analysis Section: 5 Gas Chromatography (GC) Prof. Tarek A. Fayed

Glyphosate in all its forms

LAB. FACTORS INFLUENCING ENZYME ACTIVITY

TR ACE ORGANIC. lgcstandards.com/foodandenvironment

Modelling a complex input process in a population pharmacokinetic analysis: example of mavoglurant oral absorption in healthy subjects

Effects of Aqueous Sample Content and Aqueous Co-Solvent Composition on UPC 2 Separation Performance

Lecture 22: PHARMACY CALCULATIONS for Technicians Preparing Injectable Medications

Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.

NORBUPRENORPHINE (Buprenorphine s Metabolite ) BUPRENORPHINE in urine by GC/MS Code GC Method of Confirmation by GC-MS

Nonlinear QSAR and 3D QSAR

METHADONE and EDDP in urine by GC-MS Code GC Method of Confirmation by GC-MS

PAPER AND THIN LAYER CHROMATOGRAPHY (TLC)

Evidence for the Existence of Non-monotonic Dose-response: Does it or Doesn t it?

Is sweat a suitable specimen for DUI testing?

On approximate solutions in pharmacokinetics

Water transport through the kidney

CH MEDICINAL CHEMISTRY

DETERMINATION OF GAMMA-HYDROXYBUTYRATE (GHB) BY HEADSPACE-GC/MS (FID) IN FORENSIC SAMPLES

PRINCIPLES AND PRACTICE OF BIOANALYSIS

On drug transport after intravenous administration

Compartmental Modelling: Eigenvalues, Traps and Nonlinear Models

Creatinine Microplate Assay

Internal dose assessment of 177 Lu-DOTA-SP for quantification of arginine renal protection effect

Benzoylecgonine in Urine by SAMHSA GC/MS

Analysis of Opioids Using Isotope Dilution with GCMS-TQ8030 GC/MS/MS. No. GCMS No. SSI-GCMS-1401

OPTIMISATION OF SOLID PHASE MICROEXTRACTION (SPME) CONDITIONS FOR HEADSPACE ANALYSIS OF ORGANOPHOSPHATE PESTICIDES IN WHOLE BLOOD

FORMALDEHYDE IN URINE by UV Code Z65010

Chapter 31 Gas Chromatography. Carrier Gas System

ADME SCREENING OF NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES

WATER, ACIDS, BASES, BUFFERS

Application Note. Edgar Naegele. Abstract

Application Note. Gas Chromatography/Mass Spectrometry/Food Safety. Abstract. Authors

Introduction to Pharmaceutical Chemical Analysis

Human Creatinine Serum Detection Kit

Fitting PK Models with SAS NLMIXED Procedure Halimu Haridona, PPD Inc., Beijing

Total Protein Assay Kit

Aspirin Synthesis. Figure 1 Acetylsalicylic acid (aspirin), C 9 H 8 O 4

FLUDEOXYGLUCOSE ( 18 F) INJECTION: Final text for addition to The International Pharmacopoeia (January 2009)

environmental Rtx -CLPesticides and Rtx -CLPesticides2 Columns: The Ideal Confirmational Pair for Analyzing Polychlorinated Biphenyls (PCBs)

Beka 2 Cpt: Two Compartment Model - Loading Dose And Maintenance Infusion

Calculus for the Life Sciences

Benzodiazepines and Barbiturates

Appendix II- Bioanalytical Method Development and Validation

CHEM J-3 June Calculate the osmotic pressure of a 0.25 M aqueous solution of sucrose, C 12 H 22 O 11, at 37 C

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.

Catalase Fluorometric/Colorimetric Assay Kit

TK Solver Case Study: Pharmacokinetics

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

The body has three primary lines of defense against changes in hydrogen ion concentration in the body fluids.

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE Latest Revision: August 22, 2005

Improved Extraction of THC and its Metabolites from Oral Fluid Using Oasis PRiME HLB Solid Phase Extraction (SPE) and a UPLC CORTECS C 18

INTERNAL RADIATION DOSIMETRY

The Validation of New Biokinetic Models of Thorium & Uranium using Excretion Data on Occupational Workers

Form and content. Iowa Research Online. University of Iowa. Ann A Rahim Khan University of Iowa. Theses and Dissertations

CHEMISTRY Unit 3, Area of Study 1: Chemical Analysis

ONE-COMPARTMENT KINETICS

Liquid storage: Holds the solvent which is going to act as the mobile phase. Pump: Pushes the solvent through to the column at high pressure.

C.7. DEGRADATION -ABIOTIC DEGRADATION HYDROLYSIS AS A FUNCTION OF ph

Nitric Oxide Synthase Assay Kit

Geometric series and effective medicine dosage

Exponential growth and decay models have the form y = A e bt, t 0 for constants A and b, where independent variable t usually represents time.

CHROMATOGRAPHY AND MASS SPECTROMETER

Bases of radioisotope diagnostic methods

TWO ENZYME CATALYSIS OVERVIEW OBJECTIVES INTRODUCTION

Uncontrolled Copy. SOP 109 Ethylene Glycol Screen by Gas Chromatography/Mass Spectrometry. Table of Contents. 1. Principle of Assay...

[application note] INTRODUCTION EXPERIMENTAL. Specimens. Extraction

High-sensitivity, high-throughput quantitation of catecholamine metabolites in urine by LC/MS/MS for clinical research

Chromatography & instrumentation in Organic Chemistry

Chromatographic Methods of Analysis Section - 4 : Ion Exchange Chrom. Prof. Tarek A. Fayed

LC-MS/MS in the Clinical Laboratory. Jo Adaway

CHEM 429 / 529 Chemical Separation Techniques

Homework 1 (PHA 5127)

HIPPURIC ACID, o-m-p-methylhippuric ACIDS and CREATININE IN URINE by UV CODE Z07510

Gas Chromatography. Chromatography Laboratory Course. Dr. Christian Jungnickel Chromatography Course GC September 2005

Transcription:

PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/143108 Please be advised that this information was generated on 2018-12-31 and may be subject to change.

GAS-LIQUID CHROMATOGRAPHY IN PHARMACOLOGY AND TOXICOLOGY PHARMACOKINETIC ANALYSIS LIM ITED B Y THE SEN SITIVITY OF THE AN ALYTICAL TECHNIQUE J. M. v a n R O SSU M, D. D. B R E IM E R, G. A. M. v a n G IN N E K E N, J. M. G. v a n K O R D E L A A R a n d T. B. V R E E Department of Pharmacology, Catholic University M edical School, Nijmegen (The Netherlands) SUMMARY A survey is given conserving the possibility of gas-chromatographic analysis of drugs. Attentión is paid to the plasma concentration curve, biological half-life and multicompartment kinetics. The intensity óf a drug-induced effect in man depends on the affinity to specific receptors and the concentration of such a chemical in the target tissue. This drug concentration in the receptor compartment is a function of the concentration in the blood or plasma. Although in almost all cases the drug concentration in the target tissue cannot be assessed directly, the plasma concentration may be measured, provided that sensitive analytical techniques are available. The plasma concentration curve The concentration of a drug in the plasma is a time-dependent function of the dose administered. It is a refléction of what the body does to the drug, whereas the pharmacologic response is a reflection of what the drug does to the body. As a rather extreme simplification, the human body may be considered as a single compartment into which a certain dose of a drug is introduced (Fig. i). B y analogy, such a body compartment may be seen as a reservoir with a certain volume, which is continuously cleared at a certain rate by a water flow. Obviously, the initial concentration of a drug depends on the dose and the volume of distribution, while the elimination rate at any moment depends on the concentration at that moment and the clearance (flow). In Fig. 2, plasma concentration curves are presented, following intravenous or oral administration of drugs in human subjects. The points are actual measurements, while the curves have been calculated under the assumption that the human body may be regarded as a single compartment. From the examples given, it may be Clin. Chim. Acta, 34 (19 7 1) 3 11-3 19

substance in freeh water flow ^ Fig. i. Model of the clearance of a substance from a reservoir w ith constant volum e and a schem atic presentat'on of a single com partm ent model. D = dose; K ei = elim. clearance constant. F ig. 2. Plasm a concentration curves following: (a) i.v. adm inistration of ethylbiscoum acetate (Trom exan) to a p atiën t4; (b) oral adm inistration of butobarbital to a test subject. T he half-live calculated from the slope of the curve. seen that relatively large doses were employed and that the time scale may be in minutes, hours or days: certain drugs disappear rapidly, whereas others remain in the body for a long period of time. Biological half-life and the fictive volume of distribution The rate at which a drug is eliminated from the body either by metabolism, excretion or both may be characterised by the half value time, t\. This time constant is defxned as the period of time in which 50% of the drug is eliminated from the biological object. It has therefore been called the biological half-life. Obviously, the biological half-life will be larger if the volume of distribution is larger and the clearance constant is smaller. For a relationship see Table I. It may be noted from this table Clin. Chitn. Aeta, 34 (1971) 3 11-3 19

1 T A B L E I R E L A T IO N S H IP B E T W E E N E L IM IN A T IO N C L E A R A N C E -C O N S T A N T k el, V O L U M E O F D IS T R IB U T IO N A N D E L IM IN A T IO N -T IM E -C O N S T A N T, T ej, B IO L O G IC A L -H A L F L IF E, ty, A N D E L IM IN A T IO N C O N S T A N T Assuming th at the human body m ay bc regarded as a single-com partm ental reservoir. V j Elimination process kei V f t l rtl Clearance cqual to glomerular filtration from a volum e equal to the extracellular fluid Clearance equal to urine flow from a volum e equal to total body water Clearance equal to renal plasm a flow from a volum e equal to to ta l body w ater Clearance equal to liver plasm a flow from a volum e equal to th e plasm a volum e Slow clearance from a large fictive volum e F ast clearance from a v e ry large fictive volume 130 ml/min 7.8 1/h 0.7 ml/min 42.0 ml/h 1.0 1/d 700.0 ml/min 42.0 1/h 1.0 1/min 60.0 1/h 2 m l /min 120 ml/h 120 ml/min 7.2 1/h 12 1 1 h 3 min 1 h 32 min o.o n /m in 0.65/h 36 1 576 h 25 d 864 h 36 d 0.0012/h 0.040/d 36 1 35 min 51 min 0.096/min 1.17/h 3 1 2 min 3 min 0.33/min 20.0/h 360 1 2000 h 89 d 1440 1 138 h 5-8 d 3000 h 128 d 200 h 8.3 d 0.00033/h 0.0070/d 0.0050/h 0.12/d that the apparent volume of distribution may exceed the volume of the total body water. This is because the blood or plasma concentration is the reference point. So, if a drug is preferentially taken up in certain tissues, as e.g., muscle or fat, the concentration in such tissues may be p. times the concentration in the blood so that the apparent volume of that particular tissue is p. times the actual volume. On the other hand, if a drug binds firmly to plasma proteins the apparent volume of distribution may be very small. The apparent volumes of distribution and the dose determine the concentration range in actual plasma which should be determined in order to make a study of the kinetic behaviour of a drug possible. Multicompartment kinetics When elimination from the body is slow with regard to absorption and distribution, the body may be regarded as a single compartment system. This is then likely the case for drugs with a very long half-life. For most drugs the situation is more complex or becomes more complex if the plasma curve is followed over a larger concentration range. In general, the body may be seen as a number (n) of compartments which are in exchange contact with the first or central compartment, the blood or plasma. The plasma concentration then may be described by the sum of a number of exponential terms: Ci = 27 A f «-*!** i«=i Here, Ct is the concentration at a moment t after administration of the drug. Ai is the (i) Clin. Chim. Acta, 34 (1971 ) 311-319

TIME (MINUTES) F ig. 3. B lood concentration curve of cyclo barbital in a rat, following i.v. adm inistration. N ote a biphasic decay curve. ith coëfficiënt and n the ith time constant. Persistence in the body is thus no longer characterised by the biological half-life or a single time constant, but by a number of time constants. In Fig. 3a blood concentration curve of cyclobarbital is given which has been determined in a single rat. The curve has been plotted through the measured points on basis of a two-compartment model. In general, the elimination clearance constant k,i may easily be calculated if the entire curve is analysed: kei = D-Fj Z Ai-rt (2) Here D is the dose of the drug and F the biological availability or the fraction of the dose that ultimately will be absorbed (in case of parenteral administration F = 1). It is evident that the entire plasma curve has to be determined in order to calculate the clearance constant with sufficiënt accuracy. It is obvious that thelargest product At Ti has the greatest influence on kei. This may be due mainly to a very large A t or a very large r t, or both. Kinetics of drug metabolism Most drugs are transformed in the body into several metabolites, some of which may be pharmacologically active. It is therefore not only important to have some knowledge of the kinetics of the drug or toxic agent proper, but also of its active metabolites. Clitt. Chim. Acta, 34 (1971) 3 11-3 19

A particular metabolite may be cleared at a higher rate than the parent compound and has a smaller fictive volume of distribution. The biological half-life of that metabolite is then smaller. Because of the smaller volume of distribution, relatively high concentrations may be found. This means that if reasonable concentrations of a metabolite are found, such a substance need not be of importance. On the other hand the half-life of a metabolite may be longer than that of the parent compound either because the clearance is smaller or the apparent volume of distribution is larger. Such a situation occurs for e.g. acetosal (t\ = 20 min) (aspirine) that is rapidly converted into salicylic acid (t^ 5-6 h), while both parent drug and metabolite have a similar volume of distribution of 9-1 1 1 (Fig. 4). Similar situations hold for certain psychotropic drugs, as imipramine {t\ 3 h) that is converted in desipramine {t\ = approx. 36 h) and diazepam (fy = approx. 10 h) that is converted into desmethyldiazepam (t^ = approx. 2 days). The active metabollites formed have structures strongly related to the parent drug. This implies that the analytical technique employed should be selective for each substance and preferably be carried out in a similar way. Fig. 4. (a) Plasm a concentration curve of acetosal and its m etabolite salicylic acid in a hum an; half-life of the parent drug and of th e m etabolite5. (b) Plasm a curves of Trom exan and its hydroxym etabolite4. Gas-liquid chromatography in pharmacokinetics As pointed out before, pharmacokinetic parameters may be determined with sufficiënt accuracy if the entire plasma concentration curve can be measured. This implies that a fairly large number of blood samples should be analysed while the sample size should be kept small (no more than 5 ml in man and less than 0.2 ml in rats). As a consequence of the formationof metabolites of related structure and prop- Clin. Chim. Acta, 34 (1971 ) 3 11-319

erties in the same sample, such metabolites should be determined also quantitatively. Except for those drugs that are administered in quantities of the order of grams, the concentration range in plasma is low (10 fig/ml and far less). Therefore, highly sensitive analytical techniques have to be employed. The gas-liquid chromatographic techniques using the proper column filling and the proper detector, are rather ideal for this purpose. (a) GLC with flame ionisation detection (fig quantities). For a number of drugs this method is excellent. Choosing a good column, carrier gas and oven temperature, a large number of samples may be analysed in a short time. The retention time should be short enough to assure sufficiently high sensitivity and rapid analysis (dose 100-500 mg). For most barbiturates (see Street, this symposium), this method gives very good results. Drugs given in much smaller quantities can not be analysed in most cases, unless their volume of distribution is very small. For instance, amphetamine and diazepam given in 5-25 mg quantities while their volume of distribution is more than 200 1, cannot be determined with the flame ionisation detector. This detector is not selective, so that in some cases, products normally present in the blood may interfere. (b) GLC with a nitrogen detector (ng quantities). Detectors are available that are specifically sensitive to substances containing nitrogen action. The selectivity and ECDatt16 L F ig. 5. (a) Gas chrom atogram b y using electron capture detector of chlorpheniram ine (B, 4.9 mg) added to th e sam ple and of brom pheniram ine (C) in blood of a subject receiving 8 m g.2 (b) Gas chrom atogram of lynestrenol heptafluorobutyrate, using flam e ionisation detector, (c) Electron capture detector. Note the large difference in sensitivity. Clin. Chim. Acta, 34 (1971) 311-3 19

sensitivity are greater than those of the flame ionisation detector. The method may be applied to amines and various other bioactive substances1. (c) GLC with electron capture detector (ng-pg quantities). For drugs that contai halogen atoms as in the of case chlorplieniramine, the electron capture detector may be used (Fig. 5). Sensitivity is then increased by a factor io-ioo, so that the concentration of chlorplieniramine (dose 4-12 mg) in the blood may easily be measured2. For drugs that do not contain halogen or nitro moieties, such moieties have to be introduced by quantitative synthesis. Heptafluorobutyric acid and related substances are frequently used as coupling agents3. See Fig. 5 for a lynestrenol derivative. F ig. 6. M ass-fragm entogram s of dim ethylam phetam ine and its m etabolites in th e urine of a su bject who received dim ethylam phetam ine. A bove: reference com pound; m iddle: characteristic mass fragm ent 72 of dim ethylam phetam ine; below : characteristic mass fragm ent 58 of the m etabolite metham phetamine. Clin. Chim. Acta, 34 (1971) 311-319

A disadvantage of the electron capture detector is that no large quantity of samples can be handled as the detector is easily poisoned. Furthermore, quantitative coupling procedures have to be devised for every drug and metabolite that has to be analysed. (d) Mass-fragmentography. A mass spectrometer coupled to a gas chromatograph may be used as a detector. (See Brooks, this symposium.) The intensity of certain mass lines can be Used as a measure for the amount of a drug. The method is.dependent on the mass spectrum, more sensitive than flame-ionisation detection and very selective. The method can easily be used for related compounds. For instance, a drug and its derivative in which one or more H-atoms are replaced by deuterium, may be studied at the same time. In Fig. 6 mass-fragmentograms are given for dimethylamphetamine and its metabolites in the urine of a subject to whom the drug was administered via the oral route. This method may also be used to determine the recovery of the extraction and purification procedures by adding to the sample an analogue in which deuterium is substituted for hydrogen. (e) GLC and a detector for radioactive labels. A great problem in the analysis of minute amounts of drugs in body fluids is that the purification procedure leads to variable losses. This may be controlled by adding a small amount of a highly specific radioactive labeled drug to the plasma, so that the recovery of the procedure can be checked. Pharmacokinetic analysis by indirect methods There are many drugs which are very difficuit to determine in plasma, if very low doses are given and the volume of distribution is large. (a) Urinary excretion data. Information on the biological half-life may be ob- tained indirectly by measuring the urinary excretion rate instead of the plasma disappearance rate. The renal excretion rate is directly proportional to the plasma concentration if certain restrictions are fulfilled. In formula: Where dqr/dt is the renal excretion rate and k r is the renal clearance. The quantity excreted in the urine over a period of time may be larger by several factors than the quantity in a few ml of blood (Fig. 7). (b) The plateau concentration following chronic administration. Chronic administration of a drug may result in accumulation if per unit of time more drug is absorbed than is eliminated. As a result, concentration may increase considerably. However, after a sufficiently long period of time, the concentration does not increase further and a plateau is reached. The concentration in the accumulation plateau is a simple relation to the dose and the dosage interval {dat) : Cpi = D-FIAt kei Therefore, without following the entire plasma curve, the clearance constant may be determined directly from the concentration in the plateau. Since this concentration is much higher than the maximum of the curve following a single dose, accumulation plateau concentrations may be studied initially. Clin. Chim. Acta, 34 (1971) 3 11-319

F ig. 7. B lood concentration curve of isopropyl-am phctam ine in a hum an subject sim ultaneously w ith th e concentration in the saliva, w hich is alm ost 10 tim es higher, and the renal excretion rate curve. N ote th at the curves run parallel so th a t th e biological half-life m ay be calculated from the urinary data alone. Conclusions Blood and tissue concentrations of most drugs may be determined with GLC procedures. In addition to the use of the flame ionisation detector and columns of a size normal for drugs given in reasonable doses (100-1000 mg), the combined GLC-mass spectrometry may be of extremely great help for the rapid and selective analysis of minute quantities of drugs and their metabolites. The extraction and purification procedures prior to GLC separation in general set a limit to the sensitivity, unless recovery can be brought under control. R E F E R E N C E S 1 M. v o n D o n i k e, Sportartz und Sportmedizin, 21 (1970) 27. 2 R. B. B r u c e, J. E. P i t t s a n d F. M. P i n c h b e c k, A nal. Chem., 40 (1968) 1246. 3 T. W a lle a n d H. E h rsso n, Acta Pharmacol. Suecica, 7 (1970) 389. 4 F. E. v a n D a m, Thesis, Univsrsity o f Nijmegen, Thoben-Offset, Nijm egen, T he N etherlands, 19 6 8. 5 M. R o w l a n d, S. R i e g e l m a n, P. A. H a r r i s, S. D. S h o l k o f f a n d E. J. E y r i n g, Nature, 215 (1967) 413. C lin. Chim. Acta, 34 (1971) 3 11-319